Zacks Upgrades Transcept Pharmaceuticals to Outperform (TSPT)
Transcept Pharmaceuticals (NASDAQ:TSPT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Wednesday, Stock Ratings Network reports. The firm currently has a $3.90 target price on the stock. Zacks‘ price objective would indicate a potential upside of 6.85% from the company’s current price.
Separately, analysts at MLV Capital raised their price target on shares of Transcept Pharmaceuticals from $3.00 to $4.00 in a research note to investors on Thursday, September 19th. They now have a “hold” rating on the stock. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $4.30.
Shares of Transcept Pharmaceuticals (NASDAQ:TSPT) traded down 0.27% on Wednesday, hitting $3.64. The stock had a trading volume of 106,145 shares. Transcept Pharmaceuticals has a 52 week low of $2.52 and a 52 week high of $6.77. The stock’s 50-day moving average is $3. and its 200-day moving average is $3.32. The company’s market cap is $68.3 million.
Transcept Pharmaceuticals, Inc (NASDAQ:TSPT) is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.